europe

  1. Gilead failed, but Intercept succeeded

    Last week, Gilead failed in Phase 3 clinical trial for NASH drug. Today, Intercept has become the first player in the NASH area to complete a pivotal Phase 3 study in patients with liver fibrosis.
  2. Nucynta in the EU

    Hi guys, I was wondering approximately how many people promoted Nucynta in the EU since 2013? When was the peak and how many reps were there? Thanks !
  3. Salary & Bonus EU

    Ok, let's talk about salaries and bonuses across EU & Asia... What is average salaries and bonuses in EU countries (including Russia and CIS) & Asia, and will they be payed this year?
  4. Boston Heart games

    So while all the bashing goes on and on about True Health why is no one talking about Boston actively engaging MSO schemes ie Kickbacks to physicians and waiving all copay and deductibles for OON claims? Business is being lost to these vultures for fraud and abuse practices yet crickets on the...